Retained introns contain upstream ORFs or alternative start sites producing N-terminal peptides that contain signal sequences directing co-translational ER targeting. These aberrant peptides outcompete wild-type GBA nascent chains for SRP binding, preventing proper ER targeting of wild-type GBA. Without SRP-mediated targeting, wild-type GBA misfolds in the cytosol and is degraded by proteasome. Lysosomal delivery of residual GBA is impaired due to disrupted mannose-6-phosphate tagging. Importantly, LIMP-2 enhancement represents a therapeutic strategy independent of upstream mechanism validation.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["SRP54/SRP68/SRP72 Signal Recognition Particle"]
B["Co-Translational ER Targeting Defect"]
C["SCARB2 (LIMP2) Lysosomal Targeting"]
D["Lysosomal Proteostasis Failure"]
E["Proteostatic Stress"]
F["ER Associated Degradation"]
G["Neurodegeneration Protein Misfolding"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for SRP54, SRP68, SRP72 (SRP components); SCARB2 (LIMP-2) from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMIDValidation: 0%4 supporting / 3 opposing
✓For(4)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: Intron-Retained GBA Isoform and Protein Reduction
The research question addresses how a specific intron-retaining transcript of GBA (glucosylceramidase, the gene mutated in Gaucher disease) leads to reduced protein levels and enzymatic activity—a phenomenon particularly relevant given that GBA haploinsufficiency is a major Parkinson's disease risk factor.
Hypothesis 1: Ribosome Stalling and Collision-Induced Translational Repression
Title: Cytoplasmic Intron-Retained GBA Transcripts Stall Ribosomes, Activating Collisional Quality Control That Glob
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of GBA Intron-Retention Hypotheses
Hypothesis 1: Ribosome Stalling and Collision-Induced Translational Repression
Weaknesses and Challenges
Nuclear Retention Assumption: The hypothesis assumes intron-retained GBA transcripts "escape nuclear retention," but published evidence indicates the vast majority of intron-retained transcripts are efficiently nuclear-retained, particularly in neuronal cells (Bove et al., 2021; PMID: 33711246). Only a small fraction may escape, making the overall effect potentially negligible.
**Collision Sensor Specificit
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Practical Feasibility Assessment: GBA Intron-Retention Mechanisms
Surviving Hypotheses
Based on the critique revision, the hypotheses with sufficient mechanistic support to warrant drug development consideration are:
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Dominant-Negative Spliceosome Titration","description":"Intron-retained GBA transcripts sequester core spliceosomal components (U2AF65, SF3B1, PRPF8) and snRNPs, reducing the available pool for wild-type GBA pre-mRNA processing. This cis-trans interference causes inefficient removal of downstream introns, producing additional aberrant transcripts with PTCs that are degraded by NMD, establishing a positive feedback loop that progressively depletes mature GBA mRNA and protein. The mechanism explains why a minority aberrant isoform disproportionately affects prot
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF we overexpress an N-terminal signal peptide-encoding ORF from a GBA retained intron in HEK293T cells, THEN wild-type GBA protein levels in ER-enriched fractions will decrease by >40% and cytosolic ubiquitinated GBA will increase by >50%, within 72 hours of transfection.
pendingconf: 0.65
Expected outcome: Decreased ER-localized wild-type GBA (Western blot signal reduction) and increased proteasome-degraded GBA (K48-linked ubiquitin co-immunoprecipitation)
Falsified by: Wild-type GBA ER fraction remains within 10% of baseline despite aberrant peptide overexpression at levels sufficient to alter SRP availability (confirmed by SRP54 co-IP)
Method: HEK293T cells transfected with pcDNA3.1 overexpression constructs for retained intron-derived N-terminal peptides; subcellular fractionation (differential centrifugation) and quantitative Western blot for GBA, BiP, GAPDH; ubiquitin pulldown assays
IF we achieve >2-fold overexpression of LIMP-2 (SCARB2) via lentiviral transduction in iPSC-derived neurons from GBA-associated Parkinson's disease patients, THEN lysosomal GBA activity (4-MUG hydrolysis) will increase by >30% and lysosomal GBA protein will increase by >40% compared to empty vector controls, within 21 days.
pendingconf: 0.60
Expected outcome: Increased lysosomal GBA enzymatic activity (fluorometric assay) and increased lysosomal GBA protein (by immunoprecipitation-Western blot with mannose-6-phosphate receptor enrichment)
Falsified by: Lysosomal GBA activity remains within 15% of empty vector baseline despite confirmed LIMP-2 overexpression and normal LIMP-2 trafficking to lysosomes (LIMP-2:lysosomal marker colocalization >70%)
Method: iPSC-derived dopaminergic neurons from GBA N370S carrier lines; lentiviral SCARB2 overexpression (pLenti-hSCARB2); 4-MUG hydrolysis assay at pH 4.5; density gradient lysosome isolation with Cathepsin D normalization